Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 13/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CFTR | P13569 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474229 | 0.92 | BAZ2B (0.63) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL29983936 | 0.91 | BAZ2B (0.58) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL3475272 | 0.91 | BAZ2B (0.58) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL30981939 | 0.91 | BAZ2B (0.58) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL11433133 | 0.91 | BAZ2B (0.58) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL2832897 | 0.88 | LMNA (0.76) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL30228387 | 0.88 | TRPV1 (0.59) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL21114757 | 0.87 | BAZ2B (0.71) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL5104575 | 0.87 | BAZ2B (0.71) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL16140457 | 0.87 | BAZ2B (0.71) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682146-A1 | COMPOSITION INCLUDING NOVEL PYRIDOINDOLE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES | Neurotarge Co., Ltd. (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024191255-A1 | COMPOSITION INCLUDING NOVEL PYRIDOINDOLE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES | 한국과학기술연구원 | 2024-09-19 | — | — | WO | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10570129-B2 | Carboline antiparasitics | ZOETIS SERVICES LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | BAZ2B 370/4885LMNA 2299/4885PABPC1 3880/4885 |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | BAZ2B 15/4885LMNA 4337/4885PABPC1 2898/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | BAZ2B 15/4885LMNA 4337/4885PABPC1 2898/4885 |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | BAZ2B 2299/4885LMNA 174/4885PABPC1 4206/4885 |
| US-10570129-B2 | Carboline antiparasitics | ADRA1D, DRD1, CHRM1 | BAZ2B 2076/4885LMNA 2992/4885PABPC1 4205/4885 |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | BAZ2B 370/4885LMNA 2299/4885PABPC1 3880/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | BAZ2B 15/4885LMNA 4337/4885PABPC1 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.